KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $4.8 million.

  • Emergent BioSolutions' Share-based Compensation rose 108.70% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 14.12%. This contributed to the annual value of $18.0 million for FY2024, which is 22.08% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Share-based Compensation stood at $4.8 million, which was up 4.35% from $4.6 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Share-based Compensation high stood at $12.3 million for Q2 2022, and its period low was $1.5 million during Q1 2025.
  • Its 3-year average for Share-based Compensation is $4.7 million, with a median of $4.6 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Emergent BioSolutions' Share-based Compensation was 108.70% (2025), while the steepest drop was 74.58% (2025).
  • Emergent BioSolutions' Share-based Compensation (Quarterly) stood at $10.1 million in 2021, then increased by 15.84% to $11.7 million in 2022, then tumbled by 65.81% to $4.0 million in 2023, then increased by 7.50% to $4.3 million in 2024, then skyrocketed by 108.70% to $4.8 million in 2025.
  • Its Share-based Compensation was $4.8 million in Q3 2025, compared to $4.6 million in Q2 2025 and $1.5 million in Q1 2025.